Brought to you by:
Powered by wagescape.com
Labor Market Pulse
Hagerstown-Martinsburg, MD-WV Metro Edition
Focus: LIFE SCI
Maryland biotech layoffs are filling Hagerstown's talent gap.
4.8%
Washington County unemployment
vs 4.0% Hagerstown-Martinsburg MSA, March 2026
1,200+
Maryland bioscience layoffs
Past 12 months, GSK, REGENXBIO, MacroGenics
$66,200
Lab Technician advertised pay, metro
vs $47,402 national, which is declining
6,538
Maryland statewide WARN-affected workers
Down 48% from 2025, 96 notices in 2026
This Month's Takeaways
Maryland's bioscience layoffs are Hagerstown's hiring opportunity.
Over 1,200 bioscience layoffs statewide in the past 12 months, concentrated at GSK, REGENXBIO, and MacroGenics, are pushing experienced regulatory and manufacturing talent into secondary labor markets. Leaders filling CMC or quality roles may find candidate quality improving faster than advertised pay is rising locally.
Clinical Research Associate pay is climbing faster locally than it typically would.
Metro CRA pay sits at $81,282 against a national median of $90,956, both trending up significantly — a narrowing gap that suggests Hagerstown employers are competing harder to retain clinical staff rather than losing them to larger markets. This compresses the traditional discount metro employers could expect against DC-area or Boston pay scales.
Lab Technician pay is diverging sharply from the national trend.
Metro Lab Technician pay rose significantly to $66,200 while the national median fell to $47,402 — a reversal that may reflect tighter local supply following consolidation at nearby pharma and biotech sites. Benchmarking this role against national survey data alone would understate what it now costs to fill locally.
Federal research cuts are reshaping who is available, not just how many.
HHS reductions from 82,000 to 62,000 positions are releasing scientists and regulatory staff with federal-adjacent experience into regional markets, including corridors feeding Hagerstown-Martinsburg. This shifts workforce planning from a pure pay question to a credentials-matching question — screening for regulatory pathway experience may matter more than base pay competitiveness this quarter.
Local Labor Conditions
Washington County unemployment sits at 4.8% versus the MSA's 4.0% reading, a gap that reflects Maryland's broader bioscience contraction — GSK's Shady Grove closure, REGENXBIO's 15% reduction, and MacroGenics' workforce cuts are pushing credentialed regulatory and manufacturing talent toward secondary metros like Hagerstown-Martinsburg. Federal HHS headcount reductions from 82,000 to 62,000 are compounding this supply shift, sending experienced clinical and regulatory professionals into a labor pool that local Life Sci employers can now tap at lower acquisition cost than six months ago.
Leadership & Talent Implications
Displaced talent from I-270 corridor consolidations creates a near-term sourcing opportunity for Hagerstown-area quality, manufacturing, and regulatory roles that previously required premium pay to pull candidates out of the DC/Frederick bioscience cluster. This same dynamic complicates build-vs-outsource math: CDMOs absorbing displaced capacity may offer faster scale-up than internal hires, even as available talent makes internal builds look more attractive on cost. Consider reviewing regulatory and CMC req pipelines now to capture candidates exiting GSK, REGENXBIO, and MacroGenics before competing employers in Frederick or Montgomery County do.
